Philips Respironics finalizes a consent decree with US DOJ and FDA for its US business operations.

Philips Respironics reaches a final agreement with the US DOJ and FDA on a consent decree. The decree focuses on Philips' US business operations and provides clarity and a roadmap for demonstrating compliance with regulatory requirements. Philips is committed to meeting the decree's requirements while continuing to serve healthcare providers and patients. The 2025 Group financial outlook remains unchanged.